Ultime notizie per Montauk Renewables (NASDAQ:MNTK) Azioni

Montauk Renewables

Montauk Renewables Inc is a United States-based renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments: Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.

Montauk Renewables Inc

Earnings

News

Comerica Q3 2024 Adj. EPS $1.37 Beats $1.16 Estimate, Sales $811.000M Miss $811.617M Estimate

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Adlai Nortye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANL#NASDAQ">ANL</a>) with a Buy and maintains $9 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Adlai Nortye, Maintains $9 Price Target

HC Wainwright &amp; Co. analyst Edward White maintains Aura Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AURA#NASDAQ">AURA</a>) with a Buy and raises the price target from $21 to $22.

AURA

HC Wainwright & Co. Maintains Buy on Aura Biosciences, Raises Price Target to $22

The collaboration supports the licensing of part of Curiosity Stream&#39;s content portfolio in China, Hong Kong, and Macau, bringing 56 unique titles, amounting to 148 hours of premium factual content, to audiences across these territories through various platforms. The deal encompasses a diverse range of programming, from short-form documentary series to premium long-form content.

CURI

Curiosity Inks Strategic Distribution Partnership With Off The Fence; Deal Broadens Company's Footprint Across China, Hong Kong, And Macau

Guidance

CVS's Q3 Results Won't Meet Wall Street's Expectations; Plans To Back Away From Current 2024 Guidance

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates DRDGold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRD#NYSE">DRD</a>) with a Buy and maintains $13.25 price target.

HC Wainwright & Co. Reiterates Buy on DRDGold, Maintains $13.25 Price Target

-The Wall Street Journal
-The Wall Street Journal
<a href="https://www.wsj.com/health/healthcare/cvs-names-david-joyner-as-new-chief-executive-a0a73b27" title="https://www.wsj.com/health/healthcare/cvs-names-david-joyner-as-new-chief-executive-a0a73b27">https://www.wsj.com/health/healthcare/cvs-names-david-joyner-as-new-chief-executive-a0a73b27</a>

Management

CVS Naming Caremark President David Joyner As Its New CEO

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates Avino Silver &amp; Gold Mines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASM#AMEX">ASM</a>) with a Buy and maintains $1.5 price target.

HC Wainwright & Co. Reiterates Buy on Avino Silver & Gold Mines, Maintains $1.5 Price Target

Biotech

Large Cap

Health Care

General

The European Medicines Agency's Committee For Medicinal Products For Human Use Has Adopted A Positive Opinion, Recommending Approval Of Novo Nordisk's Alhemo (Concizumab) As The First Once-Daily Subcutaneous Prophylactic Treatment For People Aged 12 Years Or Older With Hemophilia A Or B With Inhibitors.

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates First Majestic Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AG#NYSE">AG</a>) with a Buy and maintains $8.5 price target.

HC Wainwright & Co. Reiterates Buy on First Majestic Silver, Maintains $8.5 Price Target

The combined companies for the trailing twelve months have generated $235 million in revenue, increasing approximately&nbsp;25%&nbsp;quarter-over-quarter.

BTTR

Better Choice Expects Combined 2025 Pro Forma Basis Revenue And EBITDA To Be Approximately +$270M, And +$10M, Respectively

Better Choice Says Continues To Make Progress Towards Closing Of Its Acquisition Of SRx Health Solutions; Expects Transaction To Close In Late Q4 Of This Year Or Early Q1 Of 2025

Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) with a Buy and maintains $23 price target.

NMRA

Needham Reiterates Buy on Neumora Therapeutics, Maintains $23 Price Target

Based on sales trends and order intake in recent years, it expects further market share gains with domestic Chinese OEMs in the coming years.
With the seasonally strong fourth quarter remaining of the year, it reaffirms&nbsp;guidance of around 9.5-10.0% adjusted operating margin for 2024, but to be at the low end of this range.
&nbsp;

Autoliv Now Expects Full Year 2024 Organic Sales Growth To Be 1% Instead Of Previously Expected 2% Due To Unfavorable Market Mix Development

Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.53 by 7.55 percent. This is a 16.33 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $1.87 billion which beat the analyst consensus estimate of $1.80 billion by 3.78 percent. This is a 0.54 percent increase over sales of $1.86 billion the same period last year.

Earnings Beats

Regions Finl Q3 Adj $0.57 Beats $0.53 Estimate, Sales $1.87B Beat $1.80B Estimate

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $400 price target.

ALNY

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target

Autoliv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) reported quarterly earnings of $1.84 per share which missed the analyst consensus estimate of $1.95 by 5.64 percent. The company reported quarterly sales of $2.56 billion which beat the analyst consensus estimate of $2.53 billion by 0.89 percent. This is a 1.58 percent decrease over sales of $2.60 billion the same period last year.

Earnings Misses

Autoliv Q3 2024 Adj EPS $1.84 Misses $1.95 Estimate, Sales $2.56B Beat $2.53B Estimate

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) with a Buy and maintains $14 price target.

GEVO

HC Wainwright & Co. Reiterates Buy on Gevo, Maintains $14 Price Target

Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) with a Buy and maintains $22 price target.

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

Needham Reiterates Buy on Avadel Pharmaceuticals, Maintains $22 Price Target

Needham analyst Mayank Tandon maintains WNS (Hldgs) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNS#NYSE">WNS</a>) with a Buy and lowers the price target from $70 to $60.

Needham Maintains Buy on WNS (Hldgs), Lowers Price Target to $60

The Plunge Continues For Clean Energy Fuels

Warning: MNTK is at high risk of performing badly

Montauk Ag To Provide A Multi-Year Earnings Compounding Opportunity

July 2024 New Analysts Cover Rivian, McDonald's, Paycom, Spotify +

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Montauk Renewables (NASDAQ:<a href="https://investorplace.com/stock-quotes/mntk-stock-quote/">MNTK</a>) just reported results for the second quarter of 2024.<ul><li>Montauk Renewables reported earnings per share of -1 cent. This was below the analyst estimate for EPS of 7 cents.</li><li>The company reported revenue of $43.34 million.</li><li>This was 12.71% worse than the analyst estimate for revenue of $49.65 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/mntk-stock-earnings-montauk-renewables-for-q2-of-2024/">MNTK Stock Earnings: Montauk Renewables Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MNTK Stock Earnings: Montauk Renewables Misses EPS, Misses Revenue for Q2 2024

Montauk Renewables GAAP EPS of -$0.01, revenue of $43.3M

Montauk Renewables, Inc. 2024 Q2 - Results - Earnings Call Presentation

U.S. refiners cutting Q3 output across the board on weaker margins, plant overhauls

Montauk Renewables, Inc. (MNTK) Q2 2024 Earnings Call Transcript

The Top Five short crowded stocks in each U.S. sector

ACDC

APLE

ASIX

AVNW

BEPC

BIRD

BMBL

BOIL

CABO

CBRL

CERT

CIMN

CLMT

CLNE

CMTL

CUKPF

DRIP

DWLAF

ECVT

ESEA

EVTC

EWBC

GPRE

GUSH

IART

INDO

INST

KARO

KOLD

LFMD

LFMDP

LRLCF

LRLCY

MNTK

NAPA

NEWT

NTST

NXDT

OPAL

PAYC

PAYX

PDCO

RACE

REXR

RIVN

RNGR

SHIP

SIRI

SPOT

THCH

TROW

ULCC

USOI

VIST

VTLE

VTNR

WAVE

XPEV

XPNGF

YONXF

YUMC

Press Releases

Montauk Renewables Announces Third Quarter 2023 Results

Legal

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Montauk Renewables, Inc. (NASDAQ: MNTK) and Encourages Investors to Contact the Firm

Contracts

EE North America and Montauk Renewables Forge Groundbreaking Agreement for Biogenic Carbon Dioxide Delivery

Montauk Renewables Schedules Full Year 2023 Conference Call for Thursday, March 14, 2024, at 5:00 p.m. ET

Montauk Renewables Announces Full Year 2023 Results

Montauk Renewables Schedules First Quarter 2024 Conference Call for Thursday, May 9, 2024, at 5:00 p.m. ET

Montauk Renewables Announces First Quarter 2024 Results

Montauk Renewables Schedules Second Quarter 2024 Conference Call for Thursday, August 8, 2024, at 5:00 p.m. ET

Montauk Renewables Announces Second Quarter 2024 Results

Emvolon and Montauk Renewables, Inc. Announce Collaboration to Transform Methane Emissions into High-Value, Carbon-Negative Fuel

Scotiabank

B. Riley Securities

Tudor Pickering

Comments

Montauk Renewables

Notizie

Ultime notizie per Montauk Renewables (NASDAQ:MNTK) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO